KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Finished Goods: 2012-2022

Historic Finished Goods for TherapeuticsMD (TXMD) over the last 5 years, with Sep 2022 value amounting to $4.5 million.

  • TherapeuticsMD's Finished Goods rose 42.36% to $4.5 million in Q3 2022 from the same period last year, while for Sep 2022 it was $4.5 million, marking a year-over-year increase of 42.36%. This contributed to the annual value of $2.9 million for FY2021, which is 12.30% down from last year.
  • Per TherapeuticsMD's latest filing, its Finished Goods stood at $4.5 million for Q3 2022, which was up 12.50% from $4.0 million recorded in Q2 2022.
  • TherapeuticsMD's Finished Goods' 5-year high stood at $5.0 million during Q3 2019, with a 5-year trough of $1.6 million in Q1 2018.
  • For the 3-year period, TherapeuticsMD's Finished Goods averaged around $3.6 million, with its median value being $3.3 million (2020).
  • Its Finished Goods has fluctuated over the past 5 years, first surged by 122.24% in 2019, then crashed by 33.52% in 2021.
  • Quarterly analysis of 5 years shows TherapeuticsMD's Finished Goods stood at $2.9 million in 2018, then spiked by 71.09% to $5.0 million in 2019, then crashed by 32.69% to $3.4 million in 2020, then declined by 12.30% to $2.9 million in 2021, then surged by 42.36% to $4.5 million in 2022.
  • Its Finished Goods was $4.5 million in Q3 2022, compared to $4.0 million in Q2 2022 and $3.3 million in Q1 2022.